Basal-Cell Carcinoma - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Basal-Cell Carcinoma

The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform

Philip R. Cohen – 1st expert on this subject based on the ideXlab platform

  • Pigmented Basal Cell Carcinoma Masquerading as a Melanoma.
    Cureus, 2019
    Co-Authors: Boya Abudu, Philip R. Cohen


    : Basal cell Carcinoma is the most common skin cancer. Pigmented basal cell Carcinoma is an uncommon clinical presentation that can resemble a melanoma. We present the clinical and pathologic features of three individuals whose pigmented basal cell Carcinomas masqueraded as melanomas. All of the patients were Hispanic and ranged in age from 63 years to 77 years. They presented with a pigmented lesion that was ultimately diagnosed as a pigmented basal cell Carcinoma; one woman had a collision tumor consisting of a pigmented basal cell Carcinoma and a seborrheic keratosis. All of the patients had their tumors removed using Mohs micrographic surgery, without recurrence. The clinical differential diagnosis of a black tumor-particularly in patients with darker skin types-should include pigmented basal cell Carcinoma in addition to melanoma; a biopsy of the lesion will establish the diagnosis.

  • Basal Cell Carcinoma: A Patient and Physician’s Experience
    Dermatology and Therapy, 2018
    Co-Authors: Barbara J. Cohen, Eliahou S. Cohen, Philip R. Cohen


    In this article, the first coauthor, a patient with a basal cell Carcinoma on her upper lip, discusses her experience with Mohs micrographic surgery for the treatment of the skin cancer. The second coauthor, who is the patient’s physician (a dermatologist who shares her last name but is not a relative), diagnosed her skin cancer and referred her for Mohs surgery. The third coauthor, who is the patient’s son and not only a dermatologist, but also a dermatopathologist and a Mohs surgeon (and also shares her last name), summarizes the presentation and treatment of the basal cell Carcinoma.

  • Basal Cell Carcinoma with Osteoma Cutis.
    Cureus, 2018
    Co-Authors: Stella Chen, Philip R. Cohen


    : Osteoma cutis is the formation of bone within the skin. It can present as either primary osteoma cutis or secondary osteoma cutis. Secondary osteoma cutis is more common and is associated with inflammatory, infectious, and neoplastic disorders, including basal cell Carcinoma. A 79-year-old Caucasian man without underlying kidney disease or calcium abnormalities presented with a basal cell Carcinoma with osteoma cutis on the chin. Basal cell Carcinoma with osteoma cutis has seldom been described; however, the occurrence of this phenomenon may be more common than suggested by the currently published literature. The preferred treatment is surgical excision-with or without using Mohs micrographic technique. When the histopathologic examination reveals bone formation in the skin, clinicians should consider the possible presence of an adjacent malignancy, such as a basal cell Carcinoma.

Zeina Tannous – 2nd expert on this subject based on the ideXlab platform

  • real time in vivo confocal reflectance microscopy of basal cell Carcinoma
    Journal of The American Academy of Dermatology, 2002
    Co-Authors: Salvador Gonzalez, Zeina Tannous


    Abstract Background: Real-time, near-infrared confocal laser scanning microscopy may provide a way to diagnose basal cell Carcinoma in vivo and might potentially eliminate the need for invasive diagnostic biopsies in the future. Objective: The purpose of this study is to define the in vivo histologic features of basal cell Carcinoma by using a high-resolution imaging technique. Methods: Five fair-skinned white patients with 8 basal cell Carcinoma lesions were recruited for this study. Near-infrared reflectance confocal microscopy imaging was used to characterize the histologic features of these lesions in vivo. Subsequently, the confocal histologic features were correlated with the corresponding routine hematoxylin-and-eosin-stained sections obtained from invasive biopsies. Results: A uniform population of basal cell Carcinoma cells with characteristic elongated nuclei oriented along the same axis was always present. Abundant blood vessels demonstrating prominent tortuosity were seen, as well as prominent, predominantly mononuclear inflammatory infiltrate admixed or in close apposition with basal cell Carcinoma cells. Trafficking of leukocytes was visualized in real time. Conclusion: Our results demonstrate that near-infrared confocal microscopy may facilitate diagnosis of basal cell Carcinoma with the use of in vivo high-resolution confocal features. Accuracy studies to evaluate these in vivo histologic criteria are warranted. (J Am Acad Dermatol 2002;47:869-74.)

James A. Solomon – 3rd expert on this subject based on the ideXlab platform

  • Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma
    Targeted Oncology, 2019
    Co-Authors: Ralf Gutzmer, James A. Solomon


    Globally, basal cell Carcinoma is the most commonly diagnosed cancer. While most cases are amenable to surgery, treatment options for advanced basal cell Carcinoma, including locally advanced basal cell Carcinoma and metastatic basal cell Carcinoma, have proved more difficult. Recent advances regarding the role of hedgehog signaling in the pathogenesis of basal cell Carcinoma and the identification of hedgehog pathway inhibitors have facilitated the development of treatment options with improved clinical outcomes. The hedgehog signaling pathway regulates development, cell proliferation, and tissue repair. The pathway is tightly regulated under normal physiological conditions. However, dysregulated hedgehog signaling in human cancers was first described in patients with basal cell Carcinoma nevus syndrome and sporadic basal cell Carcinoma, in which germline or somatic mutations in pathway components (e.g., smoothened [Smo] and patched-1) lead to constant activation. Subsequently, inhibitors blocking hedgehog signaling either at the level of Smo (i.e., vismodegib, sonidegib, patidegib, and itraconazole) or via an unknown mode of action (arsenic trioxide) were identified. The hedgehog inhibitor vismodegib is approved for the treatment of locally advanced basal cell Carcinoma and metastatic basal cell Carcinoma while sonidegib is approved for the treatment of locally advanced basal cell Carcinoma in the USA and Europe; and for locally advanced basal cell Carcinoma and metastatic basal cell Carcinoma in Switzerland and Australia. The most common treatment-emergent adverse events associated with approved hedgehog inhibitors include muscle spasms, dysgeusia, and alopecia. This review addresses the challenges associated with appropriately diagnosing locally advanced basal cell Carcinoma, provides an overview of hedgehog signaling in basal cell Carcinoma, and discusses the pharmacology of hedgehog inhibitors and their efficacy, and adverse events associated with hedgehog inhibitor use, and their management.

  • efficacy and safety of vismodegib in advanced basal cell Carcinoma
    The New England Journal of Medicine, 2012
    Co-Authors: Aleksandar Sekulic, James A. Solomon, Michael R Migden, Anthony E Oro, L Dirix, Karl D Lewis, John D Hainsworth, Simon S Yoo, Sarah T Arron, Philip Friedlander


    Background Alterations in hedgehog signaling are implicated in the pathogenesis of Basal-Cell Carcinoma. Although most Basal-Cell Carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic Basal-Cell Carcinoma. A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced Basal-Cell Carcinoma. Methods In this multicenter, international, two-cohort, nonrandomized study, we enrolled patients with metastatic Basal-Cell Carcinoma and those with locally advanced Basal-Cell Carcinoma who had inoperable disease or for whom surgery was inappropriate (because of multiple recurrences and a low likelihood of surgical cure, or substantial anticipated disfigurement). All patients received 150 mg of oral vismodegib daily. The primary end point was the independently assessed objective response rate; the primary hypotheses were that the response rate would be greater than 20% for …